ArticleCommunications biology2021
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association.
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.International journal of cancer · 2026Review
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups.Endocrine pathology · 2026Article
- Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment.Journal of neuroendocrinology · 2026Review
- Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification.Journal of translational medicine · 2026Review
- Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape.Molecular cancer · 2026Review
- Article
- The metastatic spectrum in functional and non-functional NENs: mechanistic insights from multi-omics.Frontiers in endocrinology · 2026Review
- Expression of ATRX, DAXX, PDX1, ARX, and somatostatin receptors in pancreatic neuroendocrine tumors: a clinicopathological study.Frontiers in endocrinology · 2026Article
- Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors.Cancer metastasis reviews · 2025Review
- Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy.International journal of molecular sciences · 2025Review
- Genomic and transcriptomic landscapes of metastatic neuroendocrine neoplasms from distinct primary sites and their clinical implications.Scientific reports · 2025Article
- Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective.Endocrine-related cancer · 2025Review
- Tumor and α-SMA-expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade.Molecular oncology · 2025Article
- The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms.Endocrine · 2024Article
- Molecular Basis of Pancreatic Neuroendocrine Tumors.International journal of molecular sciences · 2024Review
- Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response.Molecular therapy. Nucleic acids · 2024Article
- Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics · 2024Review
- Review
- An Insight on Functioning Pancreatic Neuroendocrine Neoplasms.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 20 institutions in 5 countries.
Vanessa LakisQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0001-5025-8120
Rita T LawlorARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy.
Felicity NewellQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0003-0469-2705
Ann-Marie PatchQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0001-6121-4019
Andrea MafficiniARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy.ORCID 0000-0002-7471-3121
Anguraj SadanandamDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0001-8485-5150
Lambros T KoufariotisQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.
Rebecca L JohnstonQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0001-7503-9514
Conrad LeonardQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0002-4131-2065
Scott WoodQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0003-4543-8850
Borislav RusevARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy.
Vincenzo CorboARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy.
Claudio LuchiniARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy.ORCID 0000-0003-4901-4908
Sara CingarliniENETS Center of Excellence, University and Hospital Trust of Verona, Verona, Italy.
Luca LandoniENETS Center of Excellence, University and Hospital Trust of Verona, Verona, Italy.ORCID 0000-0002-2474-3496
Roberto SalviaENETS Center of Excellence, University and Hospital Trust of Verona, Verona, Italy.
Michele MilellaENETS Center of Excellence, University and Hospital Trust of Verona, Verona, Italy.
David ChangWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.ORCID 0000-0002-4821-3078
Peter BaileyWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.
Nigel B JamiesonWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.ORCID 0000-0002-9552-4725
Fraser DuthieWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.
Marie-Claude GingrasDepartment of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, MS226, Houston, Texas, 77030-3411, USA.ORCID 0000-0003-2570-6360
Donna M MuznyDepartment of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, MS226, Houston, Texas, 77030-3411, USA.
David A WheelerDepartment of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, MS226, Houston, Texas, 77030-3411, USA.ORCID 0000-0002-9056-6299
Richard A GibbsDepartment of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, MS226, Houston, Texas, 77030-3411, USA.
Massimo MilioneDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
APGI
ARC-Net
Paolo PederzoliOspedale Pederzoli, Peschiera del Garda, Verona, Italy.
Jaswinder S SamraUniversity of Sydney, Sydney, New South Wales, 2006, Australia.
Anthony J GillUniversity of Sydney, Sydney, New South Wales, 2006, Australia.
Amber L JohnsThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, Sydney, New South Wales, 2010, Australia.
John V PearsonQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.
Andrew V BiankinWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.ORCID 0000-0002-0362-5597
Sean M GrimmondUniversity of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria, 3000, Australia.ORCID 0000-0002-8102-7998
Nicola WaddellQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia.ORCID 0000-0002-3950-2476
Katia NonesQIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland, 4006, Australia. Katia.Nones@qimrberghofer.edu.au.ORCID 0000-0003-1925-5196
Aldo ScarpaARC-Net Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, 37134, Italy. aldo.scarpa@univr.it.ORCID 0000-0003-1678-739X
University of Verona · ITGarvan Institute of Medical Research · AUQIMR Berghofer Medical Research Institute · AUPrincess Alexandra Hospital · AUJohns Hopkins University · USRoyal Adelaide Hospital · AURoyal Prince Alfred Hospital · AUBankstown Lidcombe Hospital · AUBaylor College of Medicine · USFremantle Hospital · AUThe University of Sydney · AURoyal North Shore Hospital · AUSt Vincent's Hospital Sydney · AUWestmead Hospital · AUFlinders Medical Centre · AUGlasgow Royal Infirmary · GBLiverpool Hospital · AUPrince of Wales Hospital · AUThe University of Melbourne · AUUniversity of Glasgow · GB
Funding
The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MCancer Research UK 25813Cancer Research UK C29717/A17263Cancer Research UK C29717/A18484Cancer Research UK C596/A18076Cancer Research UK C596/A20921NHGRI NIH HHS U54 HG003273Wellcome Trust
Abstract
Here we report the DNA methylation profile of 84 sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 and T3, with distinct patterns of methylation. The T1 subgroup was enriched for functional tumors and ATRX, DAXX and MEN1 wild-type genotypes. The T2 subgroup contained tumors with mutations in ATRX, DAXX and MEN1 and recurrent patterns of chromosomal losses in half of the genome with no association between regions with recurrent loss and methylation levels. T2 tumors were larger and had lower methylation in the MGMT gene body, which showed positive correlation with gene expression. The T3 subgroup harboured mutations in MEN1 with recurrent loss of chromosome 11, was enriched for grade G1 tumors and showed histological parameters associated with better prognosis. Our results suggest a role for methylation in both driving tumorigenesis and potentially stratifying prognosis in PanNETs.
Indexed as
DNA MethylationEpigenesis, GeneticEpigenomeBiomarkers, TumorCarcinoma, NeuroendocrineEpigenomicsGenetic Predisposition to DiseaseHumansNeoplasm GradingPancreatic NeoplasmsPhenotypeTumor BurdenBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.